Quest Diagnostics Shares Hit Record High on Robust Annual Outlook

The diagnostic services provider reported fourth-quarter revenue of $2.81 billion, a 7.1% increase that surpassed analyst expectations of $2.75 billion. Adjusted earnings per share reached $2.42, outperforming the $2.36 projected by FactSet. This financial momentum propelled the stock up nearly 5% to $200.53 in midday trading, following an earlier session peak of $204.90.

Growth Driven by Preventative Care

For the full year, Quest Diagnostics now projects adjusted earnings between $10.50 and $10.70 per share, with revenue expected to reach up to $11.82 billion. This guidance sits comfortably above the $11.38 billion revenue consensus previously held by analysts. Chief Executive Jim Davis attributed the optimistic outlook to favorable market fundamentals, specifically citing an aging population and the growing adoption of blood-based lab diagnostics in routine wellness monitoring.

To further bolster investor confidence, the company announced a $1 billion increase to its share repurchase authorization and raised its quarterly dividend. The stock has climbed approximately 23% over the last 12 months, reflecting a broader market pivot toward healthcare leaders with stable cash flows and clear growth trajectories in the diagnostic space.